A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
Clinical trial NCT03625466 · COMPLETED
Trial details
- NCT number
- NCT03625466
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-10
- Primary completion
- 2020-10-09
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.